Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
27 December 2023
GenSight Biologics Provides Business and Financial Update
22 December 2023
GenSight Biologics appoints Laurence Rodriguez as Chief Executive Officer
22 November 2023
GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris
21 November 2023
GenSight Biologics announces a successful offering for an amount of approximately €4.7 million
20 November 2023
GenSight Biologics announces launch of an offering for an indicative amount of €5 million that has received subscription commitments from new and existing shareholders totaling €4 million
15 November 2023
GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million
13 November 2023
GenSight Biologics Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch
26 October 2023
GenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business Update
27 September 2023
GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®
18 September 2023
GenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP Batch
View previous 9 articles
1
2
3
4
5
6
7
8
…
24
View next 9 articles
Go back to the page of the page